Sign up to save your podcastsEmail addressPasswordRegisterOrContinue with GoogleAlready have an account? Log in here.
July 10, 2024Carlo Antozzi, MD - From Helsinki: Expert Perspectives on the Next Generation of Clinical Evidence for FcRn Inhibitors in Myasthenia Gravis20 minutesPlayCarlo Antozzi, MD - From Helsinki: Expert Perspectives on the Next Generation of Clinical Evidence for FcRn Inhibitors in Myasthenia Gravis...moreShareView all episodesBy PeerVoice4.844 ratingsJuly 10, 2024Carlo Antozzi, MD - From Helsinki: Expert Perspectives on the Next Generation of Clinical Evidence for FcRn Inhibitors in Myasthenia Gravis20 minutesPlayCarlo Antozzi, MD - From Helsinki: Expert Perspectives on the Next Generation of Clinical Evidence for FcRn Inhibitors in Myasthenia Gravis...moreMore shows like PeerVoice Internal Medicine AudioView allPeerVoice Oncology & Haematology Audio1 ListenersPeerVoice Heart & Lung Video0 ListenersPeerVoice Endocrinology & Metabolic Disorders Audio7 ListenersPeerVoice Endocrinology & Metabolic Disorders Video2 ListenersPeerVoice Digestive Diseases Audio0 ListenersPeerVoice Digestive Diseases Video0 ListenersPeerVoice Immunology & Infectious Disease Video0 ListenersPeerVoice Immunology & Infectious Disease Audio1 ListenersPeerVoice Internal Medicine Video0 ListenersJAMA Clinical Reviews496 ListenersCore IM | Internal Medicine Podcast1,095 ListenersAnnals On Call Podcast185 ListenersThe Clinical Problem Solvers519 ListenersRun the List248 ListenersMayo Clinic Center for Sleep Medicine3 Listeners
Carlo Antozzi, MD - From Helsinki: Expert Perspectives on the Next Generation of Clinical Evidence for FcRn Inhibitors in Myasthenia Gravis
July 10, 2024Carlo Antozzi, MD - From Helsinki: Expert Perspectives on the Next Generation of Clinical Evidence for FcRn Inhibitors in Myasthenia Gravis20 minutesPlayCarlo Antozzi, MD - From Helsinki: Expert Perspectives on the Next Generation of Clinical Evidence for FcRn Inhibitors in Myasthenia Gravis...more
Carlo Antozzi, MD - From Helsinki: Expert Perspectives on the Next Generation of Clinical Evidence for FcRn Inhibitors in Myasthenia Gravis